The gore® cardioform septal occluder instructions for states: adverse events associated with the use of the occluder may include but are not limited to: device embolization.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
It was reported to gore a 25mm gore® cardioform septal occluder was implanted on (b)(6) 2023 to treat a patent foramen ovale.It was noted on echocardiogram prior to discharge on (b)(6) 2023 that the device had embolized to the abdominal aorta.The physician attempted to snare the device thru the femoral artery, however, was unsuccessful as the device became entrapped in the femoral vessel.A vascular surgeon performed a cutdown procedure and successfully removed the device.It was reported the patient tolerated the procedure and will be brought back at a later date for closure of the defect.
|